<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="49882">Rhenium</z:chebi>-188 (beta- = 2.2 MeV; gamma = 155 keV; T1/2 16.9 hours) is an attractive therapeutic radioisotope which is produced from decay of the reactor-produced <z:chebi fb="66" ids="27998">tungsten</z:chebi>-188 parent (T1/2 69 days) and thus conveniently obtained on demand by elution from the <z:chebi fb="22" ids="30187">alumina</z:chebi>-based <z:chebi fb="66" ids="27998">tungsten</z:chebi>-188 /<z:chebi fb="0" ids="49882">rhenium</z:chebi>-188 generator system </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:chebi fb="0" ids="49882">rhenium</z:chebi>-188 is obtained as <z:chebi fb="199" ids="26708">sodium</z:chebi> perrhenate by elution of the generator with 0.9% saline </plain></SENT>
<SENT sid="2" pm="."><plain>The post elution use of disposable tandem, ion-exchange columns is a simple method for the concentration of <z:chebi fb="0" ids="49882">rhenium</z:chebi>-188 saline solutions with specific volumes &gt; 500 mCi/ml </plain></SENT>
<SENT sid="3" pm="."><plain>This method can also extend the useful shelf-life of the generator, which can be as long as one year </plain></SENT>
<SENT sid="4" pm="."><plain>The long useful shelf-life of the generator is expected to provide <z:chebi fb="0" ids="49882">rhenium</z:chebi>-188 at very reasonable costs for routine preparation of a variety of radiopharmaceuticals for the treatment of a variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> including <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>We are evaluating two types of Re-188-labeled agents under investigation which have potential for the treatment of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="49882">Rhenium</z:chebi>-188-labeled hydroxyethylidenediphosphonate (HEDP) and Re-188-dimercaptosuccinic acid (DMSA) are being applied for palliative treatment of pain associated with skeletal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, and the Re-188-RC-160 somatostatin analogue [cyclic <z:chebi fb="0" ids="29337,29340">NH2-</z:chebi>(D)-Phe-Cys-Try-(D)<z:chebi fb="0" ids="32708">-Trp</z:chebi>-Lys-Val-Cys<z:chebi fb="0" ids="32708">-Trp</z:chebi>-<z:chebi fb="0" ids="29318,29339">NH2</z:chebi>] for somatostatin-receptor-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The results of initial clinical studies with the two <z:hpo ids='HP_0002653'>bone pain</z:hpo> agents demonstrate good targeting to skeletal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, and use of Re-188-HEDP has resulted in pain palliation with minimal bone marrow suppression in the initial patient studies </plain></SENT>
<SENT sid="8" pm="."><plain>While these initial studies have been conducted in patients with <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, similar results are expected in planned studies in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> patients </plain></SENT>
<SENT sid="9" pm="."><plain>In animal studies, Re-188-RC-160 has been successfully used for the local/regional treatment of experimental <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Re-188-RC-160 binds to somatostatin-receptor-positive cells both in vitro and in vivo, including <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cells (ZR-75-1 <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> and NCI-H69 human small cell ling <z:mp ids='MP_0002038'>carcinoma</z:mp>), but not to binding-negative cells (Raji, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="11" pm="."><plain>A structurally similar Re-188-<z:chebi fb="0" ids="23449">cyclic peptide</z:chebi> with different binding specificity (CTOP [cyclic <z:chebi fb="0" ids="29337,29340">NH2-</z:chebi>(D)-Phe-Cys-Try-(D)<z:chebi fb="0" ids="32708">-Trp</z:chebi><z:chebi fb="6" ids="44548">-Orn</z:chebi>-Thr-Pen-Thr-ol]; an opiate-receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>) did not bind to target cells </plain></SENT>
<SENT sid="12" pm="."><plain>Both gentisic acid and <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> are present in the Re-188-HEDP and Re-188-RC-160 formulations, and have been found to also significantly reduce radiolytic degradation of the somatostatin <z:chebi fb="7" ids="16670">peptide</z:chebi> analogues, and may have general application in the stabilization of Re-188-labeled radio-pharmaceuticals </plain></SENT>
</text></document>